Pipelinepharma is a clinical-stage biopharmaceutical company developing small-molecule therapies for neurodegenerative, inflammatory, and immunological conditions with significant unmet medical needs. The company's lead asset, PIPE-791, is a brain-penetrant LPA1 receptor antagonist being developed for idiopathic pulmonary fibrosis and chronic pain, while a partnered program, PIPE-307, targets depression and multiple sclerosis through muscarinic type 1 receptor inhibition under a collaboration with Johnson & Johnson. Pipelinepharma generates revenue primarily through its partnership with J&J, which includes an upfront payment, equity investment, potential milestone payments up to approximately one billion dollars, and royalties on net sales; for its lead owned asset, the company plans to commercialize through an internal sales organization in the United States and establish international collaborations.